THRD: Third Harmonic Bio Inc. Company Value to Net Income
This price chart for Third Harmonic Bio (THRD) featuring the -4.60 metric illustrates the dynamics of the company developing anti-inflammatory agents. Currently, pricing leverage depends on the test results of drugs targeting mastocytosis. However, selective KIT inhibitors enable the suppression of dermatitis, rendering demand inelastic. The exclusivity of mast cell-suppressing molecules promises a breakthrough in urticaria therapy and significant pricing power.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_THRD_-_Third-Harmonic-Bio_-_PE-Multiple "THRD: Third Harmonic Bio Business Payback Period 04/28/2023 - 08/16/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for Third Harmonic Bio, Inc (THRD)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Third Harmonic Bio|THRD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Third Harmonic Bio Inc|THRD - Company Debts|Debt to Book Value Ratio Third Harmonic Bio, Inc.|THRD - Company Long-Term Debts|Short-Term Debt Third Harmonic Bio|Intermediate Liquidity Ratio thirdharmonicbio.com
- earnings and market multiples details:
THRD - Net Profit|Expected Net Income Third Harmonic Bio|THRD - P/E Multiple|Market Cap to Projected Earnings Third Harmonic Bio Inc.|THRD - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Third Harmonic Bio, Inc.|THRD - Operating profit EBITDA|Earnings per share for the last 12 months Third Harmonic Bio|THRD - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months thirdharmonicbio.com|THRD - Earnings growth in current year|Expected earnings per share trend next year Third Harmonic Bio
Comprehensive company analysis:thirdharmonicbio.com THRD
For the biopharmaceutical sector where Third Harmonic Bio (THRD) operates, P/E valuation dynamics reflect market expectations for future earnings. This indicator is calculated as the ratio of the current share price to earnings per share. The metric determines the extent to which an investor is overpaying for every dollar of income. The company's stable cash flow and controlled burn rate mitigate the volatility of this ratio. Analysis of the chart allows for the timely identification of asset overheating or undervaluation phases.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL: Price to Earnings Ratio|Tourmaline - Market Price to Net Income Ratio|PGEN: P/E Multiple|pharming.com - Company Value to Net Income|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Upstream Bio, Inc. (UPB) - Business Payback Period|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM (Immunome Bio) - Company Value to Net Income|P/E Multiple GOSS (Gossamer Bio, Inc.)|KALV: Price to Earnings Multiple|SEPN: Price to Earnings Ratio|Company Value to Net Income PVLA (Pieris Pharma)|SVRA: P/E Multiple|Rigel Corp - Company Value to Net Income|ANAB (AnaptysBio, Inc.) - P/E Multiple|P/E Multiple astriatx.com|Price to Earnings Ratio enGene (ENGN)|RAPT (RAPT Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Aerovate Therapeutics JBIO|ACRS - Price to Earnings Ratio|KYTX - Price to Earnings Ratio|Market Cap to Earnings tizianalifesciences.com|Cabaletta Bio (CABA) - Price to Earnings Ratio|Price to Earnings Multiple VTYX|THTX (Theratechnologies Inc) - P/E Multiple|Avalo Therapeutics Inc (AVTX) - Business Payback Period|P/E Multiple ELDN|Price to Earnings Ratio agenusbio.com AGEN|Climb Bio - Price to Earnings Ratio|Company Value to Net Income ZURA|aTyr - P/E Multiple|ADAG: Price to Earnings Ratio|IMA: P/E Multiple|STTK - Business Payback Period|Price to Earnings Ratio Equillium Inc|Market Cap to Earnings Connect Pharma CNTB|Price to Earnings Ratio IMUX (Immunic, Inc.)|Market Price to Net Income Ratio ATRA|P/E Multiple IFRX (InflaRx)|Company Value to Net Income XFOR|ACET - Price to Earnings Ratio|Company Value to Net Income CELU (Celularity Inc.)|INMB: P/E Multiple|Price to Earnings Multiple BRNS|Price to Earnings Ratio Kezar Life Sciences|sabbiotherapeutics.com - Market Cap to Net Income|P/E Multiple AKTX|ENLV (enlivex.com) - Company Value to Net Income|P/E Multiple QTTB (Q32 Bio)|P/E Multiple GeoVax Corp GOVX|EDSA - Price to Earnings Ratio|Company Value to Net Income IBIO (ibioinc.com)|carismatx.com (CARM) - Price to Earnings Ratio|Price to Earnings Ratio XTL Biopharmaceuticals Ltd|BOLT (Bolt Biotherapeutics Inc.) - P/E Multiple|P/E Multiple HCW Biologics Inc|Price to Earnings Ratio APVO (Aptevo Therapeutics)|AIM (AIM ImmunoTech, Inc.) - Company Value to Net Income|P/E Multiple ADTX (Aditxt, Inc.)|Business Payback Period GRI Bio Inc (GRI)|XRTX - Price to Earnings Ratio|Vyome Therapeutics (HIND) - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|Price to Earnings Ratio indaptusrx.com|Price to Earnings Ratio SCNI|P/E Multiple CalciMedica Corp|Price to Earnings Ratio Affimed (AFMD)|allakos.com - Price to Earnings Multiple|P/E Multiple HOOK (HOOKIPA Pharma)|IGM Biosciences Inc. (IGMS) - Market Cap to Earnings|ITOS: Price to Earnings Ratio|Ocean Biomedical Inc - Market Price to Net Income Ratio|TCBP: P/E Multiple
